SERD Therapeutics Market Size, Share & Trends Analysis Report By Products (Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products), By Route of Administration, By Indication, Region, And Segment Forecasts, 2025-2034
Global SERD Therapeutics Market Size is valued at USD 1339.0 Mn in 2024 and is predicted to reach USD 2108.7 Mn by the year 2034 at a 4.8% CAGR during the forecast period for 2025-2034.
Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD treats estrogen receptor-positive breast cancer. SERD therapy can be used as both monotherapies and in combination with other therapeutic agents. Many key market players are engaged in developing new breast cancer therapies that would propel the growth of this market.
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, the rising number of clinical trials, and increasing investments by key players in the development of promising treatments. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market during the forecast period. However, the high price of devices, complex procedures, lack of strict government laws, and resistance to endocrine Therapy are limiting the growth of this market.
Market Segmentation
The SERD therapeutics market is segmented into Products, Route of Administration, Indication and Region. On the basis of Products, market is segmented into Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products. The Route of Administration segments consists of Intramuscular, Oral, Infusion, Subcutaneous, Parenteral, and Other. On the basis of Indications, segment includes ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer and Other.
Regionally, the SERD therapeutics market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, major market players, and the fast adaption of advanced technologies.
Major vital Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players.
Competitive Landscape
Some of The Key Players in The SERD Therapeutics Market:
- Amneal Pharmaceuticals Inc
- AstraZeneca, Plc.
- Reddy’s Laboratories
- Eli Lilly and Company
- G1 Therapeutics, Inc.
- Glenmark Pharmaceuticals
- HBT Labs, Inc
- Hoffmann-La Roche AG
- InventisBio
- Novartis AG
- Radius Health
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zenopharm LLC.
- Zentalis Pharmaceuticals
- Genentech
- Olema Pharmaceuticals
- Aragon Pharmaceuticals
- Sun Pharma Advanced Research Company
- Shandong Luoxin Pharmaceutical
- Zeno Alpha
- Atossa Therapeutics
- Evestra
SERD Therapeutics Market Report Scope:
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1339.0 Mn |
| Revenue Forecast In 2034 | USD 2108.7 Mn |
| Growth Rate CAGR | CAGR of 4.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Route of Administration, By Indication |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, Genentech, Olema Pharmaceuticals, Aragon Pharmaceuticals, Sun Pharma Advanced Research Company, Shandong Luoxin Pharmaceutical Zeno Alpha, Atossa Therapeutics, Evestra and Others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of SERD Therapeutics Market
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Products
- Faslodex
- Elacestrant
- Camizestrant (AZD9833)
- Giredestrant (GDC-9545)
- Imlunestrant (LY3484356)
- Other Pipeline Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Route Of Administration
- Intramuscular
- Oral
- Infusion
- Subcutaneous
- Parenteral
- Other
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Indication
- ER-positive
- HER2-negative
- ESR1-mutated advanced or metastatic breast cancer
- Other
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
- U.S.
- Canada
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Landscape
- Company Overview
- Financial Performance
- Key Development
Latest Strategic Developments
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
SERD Therapeutics Market Size is valued at USD 1339.0 Mn in 2024 and is predicted to reach USD 2108.7 Mn by the year 2034
Global SERD Therapeutics Market is expected to grow at a 4.8% CAGR during the forecast period for 2025-2034.
Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT L
Products, Route of Administration, and Indication are the key segments of the SERD Therapeutics Market.
North American region is leading the SERD Therapeutics Market.